Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report

Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report

Primary humoral deficiency and secondary B-cell depletion may lead to prolonged Sars-Cov-2 infection due to a decreased viral clearance. Prolonged infection is mainly driven by the lack of anti-Sars-Cov-2 immunoglobulin (IVIg) especially in patients with no vaccine response. Anti-spike immunoglobuli...

Full description

Bibliographic Details
Main Authors: Bénédicte Billi, Paul Cholley, Vincent Grobost, Mélissa Clément, Virginie Rieu, Guillaume Le Guenno, Hervé Lobbes
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
immunodeficiency
B-cell depletion
rituximab
intravenous immunoglobulin
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1399180/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1399180/full

Similar Items